M
Martin Empting
Researcher at Saarland University
Publications - 76
Citations - 2235
Martin Empting is an academic researcher from Saarland University. The author has contributed to research in topics: Pseudomonas aeruginosa & Quorum sensing. The author has an hindex of 24, co-authored 68 publications receiving 1534 citations. Previous affiliations of Martin Empting include Technische Universität Darmstadt.
Papers
More filters
Journal ArticleDOI
Towards the sustainable discovery and development of new antibiotics
Marcus Miethke,Marco Pieroni,Tilmann Weber,Mark Brönstrup,Peter Hammann,Ludovic Halby,Paola B. Arimondo,Philippe Glaser,Bertrand Aigle,Helge B. Bode,Helge B. Bode,Rui Moreira,Yanyan Li,Andriy Luzhetskyy,Marnix H. Medema,Jean-Luc Pernodet,Marc Stadler,José R. Tormo,Olga Genilloud,Andrew W. Truman,Kira J. Weissman,Eriko Takano,Stefano Sabatini,Evi Stegmann,Heike Brötz-Oesterhelt,Wolfgang Wohlleben,Myriam Seemann,Martin Empting,Anna K. H. Hirsch,Brigitta Loretz,Claus-Michael Lehr,Alexander Titz,Jennifer Herrmann,Timo Jaeger,Silke Alt,Thomas Hesterkamp,Mathias Winterhalter,Andrea Schiefer,Kenneth Pfarr,Achim Hoerauf,Heather Graz,Michael Graz,Mika Lindvall,Savithri Ramurthy,Anders Karlén,Maarten van Dongen,Hrvoje Petković,Andreas Keller,Frédéric Peyrane,Stefano Donadio,Laurent Fraisse,Laura J. V. Piddock,Ian H. Gilbert,Heinz E. Moser,Rolf Müller +54 more
TL;DR: In this paper, the authors present a strategic blueprint to substantially improve our ability to discover and develop new antibiotics, and propose both short-term and long-term solutions to overcome the most urgent limitations in the various sectors of research and funding.
Journal ArticleDOI
Novel Strategies for the Treatment of Pseudomonas aeruginosa Infections
Stefanie Wagner,Roman Sommer,Stefan Hinsberger,Cenbin Lu,Rolf W. Hartmann,Martin Empting,Alexander Titz +6 more
TL;DR: It can be expected that combination therapies, also containing antivirulence agents, will pave the way toward novel treatment options against P. aeruginosa, and antivirulent drugs are expected to yield a significantly reduced rate of resistance development.
Journal ArticleDOI
Camelid and shark single domain antibodies: structural features and therapeutic potential.
Doreen Könning,Stefan Zielonka,Julius Grzeschik,Martin Empting,Bernhard Valldorf,Simon Krah,Christian Schröter,Carolin Sellmann,Björn Hock,Harald Kolmar +9 more
TL;DR: Heavy-chain only isotypes (HcAb) devoid of light chains, where antigen-binding is mediated exclusively by one variable domain, evolved as promising candidates for biomedical applications of which many have already proven to be successful in early stage clinical trials.
Journal ArticleDOI
"Triazole bridge": disulfide-bond replacement by ruthenium-catalyzed formation of 1,5-disubstituted 1,2,3-triazoles.
Martin Empting,Olga Avrutina,Reinhard Meusinger,Sebastian Fabritz,Michael Reinwarth,Markus Biesalski,Stephan Voigt,Gerd Buntkowsky,Harald Kolmar +8 more
TL;DR: The facile introduction of 1,4-disubstituted 1,2,3-triazoles into peptides and the compelling characteristics of this prototypic “click” reaction, which has been extensively applied in peptide chemistry exploiting the almost perfect orthogonality to side-chain reactivities are reported.
Journal ArticleDOI
Structural insights and biomedical potential of IgNAR scaffolds from sharks
Stefan Zielonka,Martin Empting,Julius Grzeschik,Doreen Könning,Caroline J. Barelle,Harald Kolmar +5 more
TL;DR: This review highlights the structural features of vNAR molecules, addresses aspects of their generation using immunization or in vitro high throughput screening methods and provides examples of therapeutic, diagnostic and other biotechnological applications.